Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Laban

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
International Journal of Cancer|August 14, 2019
Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus statusDominik S Gangkofner, Dana Holzinger, Lea Schroeder, et al.
The Lancet. Oncology|April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2019
Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma PatientsSimon Laban, Dominik S Gangkofner, Dana Holzinger, et al.
The New England Journal of Medicine|June 18, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Robert I Haddad, Yungan Tao, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
International Journal of Cancer|August 14, 2019
Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus statusDominik S Gangkofner, Dana Holzinger, Lea Schroeder, et al.
The Lancet. Oncology|April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2019
Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma PatientsSimon Laban, Dominik S Gangkofner, Dana Holzinger, et al.
The New England Journal of Medicine|June 18, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Robert I Haddad, Yungan Tao, et al.
Pageof 10